Coherus Gets Goal Date On US Adalimumab Biosimilar
Firm Sees ‘Pent-Up Demand’ For Potential $18bn Humira Target
A further FDA approval for a biosimilar to Humira could be on the cards, after Coherus revealed the agency’s goal date for its CHS-1420 adalimumab application.
You may also be interested in...
Coherus BioSciences is aiming to translate the success of its comprehensive biosimilar pegfilgrastim strategy to adalimumab, with plans to capture at least 10% of the US market upon formation in 2023. Management summarized the firm’s expectations during the company’s fourth-quarter earnings call, which revealed a downturn in pegfilgrastim sales and profitability.
Keeping Track: Novartis Entresto Wins Expanded Heart Failure Claim; Padcev, Vicineum Seek Bladder Cancer Approvals
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Sandoz has confirmed the launch of its Hyrimoz biosimilar rival to Humira in Canada, with other biosimilars firms having also set their sights on a mid-February launch.